New hope for endometrial cancer: targeted drug plus chemo shows promise
NCT ID NCT07170982
First seen Oct 31, 2025 · Last updated Jun 22, 2026 · Updated 30 times
Summary
This phase 2 trial tests whether adding the targeted drug fruquintinib to standard chemotherapy (paclitaxel and carboplatin) works better than chemo alone for advanced or recurrent endometrial cancer that is mismatch repair-proficient (pMMR). About 128 participants will be randomly assigned to receive either the combo or chemo alone. The goal is to see if the combo shrinks tumors more effectively and delays cancer growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Gynecologic Oncology, Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
fruquintinib (a targeted cancer drug taken orally) combined with paclitaxel and carboplatin (standard chemotherapy)
What this could lead to
If successful, this could offer a new first-line treatment option for advanced pMMR endometrial cancer, potentially improving tumor shrinkage and delaying disease progression.
What could go wrong
This is an early phase 2 trial with only 128 participants, so results may not be definitive. The drug combination may cause side effects or fail to show benefit over standard chemo alone.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.